ClinVar Miner

Submissions for variant NM_004333.5(BRAF):c.1406G>A (p.Gly469Glu) (rs121913355)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 18
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000506575 SCV000602657 pathogenic not specified 2017-03-10 criteria provided, single submitter clinical testing
Baylor Miraca Genetics Laboratories, RCV000033307 SCV000196670 pathogenic Rasopathy no assertion criteria provided clinical testing Variant classified using ACMG guidelines
ClinGen RASopathy Variant Curation Expert Panel RCV000211748 SCV000616361 pathogenic Cardio-facio-cutaneous syndrome 2017-04-03 reviewed by expert panel curation The c.1406G>A (p.Gly469Glu) variant in BRAF has been reported in the literature as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 18042262, 16474404). In vitro functional studies provide some evidence that the p.Gly469Glu variant may impact protein function (PS3; 16474404). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Furthermore, this variant is in a location which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly469Glu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS2_VeryStrong, PS3.
Database of Curated Mutations (DoCM) RCV000424773 SCV000504335 pathogenic Neoplasm of the large intestine 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000434590 SCV000504336 likely pathogenic Adenocarcinoma of prostate 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000443381 SCV000504337 likely pathogenic Multiple myeloma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000427215 SCV000504338 likely pathogenic Cutaneous melanoma 2015-07-14 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000437869 SCV000504339 likely pathogenic Squamous cell carcinoma of the skin 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000419576 SCV000504340 likely pathogenic Transitional cell carcinoma of the bladder 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000427006 SCV000504341 likely pathogenic Squamous cell lung carcinoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000436804 SCV000504342 likely pathogenic Lung adenocarcinoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000419555 SCV000504343 likely pathogenic Malignant melanoma of skin 2016-05-31 no assertion criteria provided literature only
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000212152 SCV000225337 pathogenic not provided 2014-07-27 criteria provided, single submitter clinical testing
Foundation for Research in Genetics and Endocrinology,Institute of Human Genetics RCV000015008 SCV000747832 pathogenic Cardiofaciocutaneous syndrome 1 2017-12-25 no assertion criteria provided clinical testing The observed variant c.1406G>A (p.G469E) is not reported in 1000 Genomes and has a minor allele frequency of 0.000008238 in ExAC databases. The in silico prediction of the variant is disease causing by MutationTaster2, damaging by SIFT, and probably damaging by PolyPhen2.
GeneDx RCV000212152 SCV000057212 pathogenic not provided 2017-01-10 criteria provided, single submitter clinical testing The G469E pathogenic variant in the BRAF gene has been reported previously in association with Cardio-Facio-Cutaneous (CFC) syndrome, including de novo occurrences (Niihori et al., 2006; Schulz et al., 2008; Sarkozy et al., 2009). It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. G469E is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position within the ATP nucelotide binding region of the protein kinase domain that is conserved across species and in silico analysis predicts this variant is probably damaging to the protein structure/function. Missense variants at the same (G469R) and in nearby residues (G464R/V, S467A, F468S, T470P) have been reported in the Human Gene Mutation Database in association with cardio-facio-cutaneous syndrome (Stenson et al., 2014), supporting the functional importance of this region of the protein. Additionally, functional studies of the G469E variant have shown that it results in reduced B-Raf protein activity and decreased induction of MEK and ERK phosphorylation (Rodriguez-Viciana et al., 2006; Niihori et al., 2006). Therefore, we interpret the G469E variant as pathogenic.
Invitae RCV000033307 SCV000553832 pathogenic Rasopathy 2016-04-24 criteria provided, single submitter clinical testing This sequence change replaces glycine with glutamic acid at codon 469 of the BRAF protein (p.Gly469Glu). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. This variant is present in population databases at a very low frequency (rs121913355, ExAC <0.01%). This variant has been reported in the literature in individuals affected with cardiofaciocutaneous syndrome (PMID: 16474404, 19206169, 18042262, 16439621). In at least one individual this change was reported to be a de novo event and was not present in the proband's unaffected parents (PMID: 18042262). ClinVar contains an entry for this variant (Variation ID: 13974) Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies. In summary, this is a rare missense change that is predicted to disrupt protein function and has been reported in multiple affected individuals. For these reasons, it has been classified as Pathogenic.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000211748 SCV000061581 pathogenic Cardio-facio-cutaneous syndrome 2011-07-26 criteria provided, single submitter clinical testing The Gly469Glu variant has been reported in the literature in several individuals with clinical features of Cardio-facio-cutaneous syndrome (Niihori 2006, Schulz 2008). In addition, this variant was reported to have occurred de novo in three of those individuals. Therefore, this variant is highly likely to be pathogenic.
OMIM RCV000015008 SCV000035264 pathogenic Cardiofaciocutaneous syndrome 1 2006-03-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.